IPO Date: TBC
Compass Therapeutics, Inc. American company, creator of innovative low molecular weight drugs in the field of oncological and hematological diseases.
💎 Unique developments in the field of potential treatment of a wide range of cancer diseases with StitchMabs proprietary platform for growing monoclonal antibodies. The company can not only monetize by selling revolutionary molecules to other companies, but also has the opportunity to use its developments to create its own drugs.
💰 The global market for breast cancer treatment (one of the main profiles of CTX-471) is estimated at $ 9.9 billion by 2025.
💎 IPO. Compass is seeking a smaller than average IPO transaction to advance its various programs through and into clinical trials. For its lead candidate, CTX-471, the firm is currently conducting Phase 1 safety trials. Management intends to complete Phase 1 dosing trials by the second half of 2021 and to begin Phase 2 / 3 trials by early 2022. Citigroup is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of negative (5.4%) since their IPO. This is a lower-tier performance for all major underwriters during the period. As to valuation, the IPO is valued on the lower end of the typical range for a clinical stage biopharma firm at IPO, so appears reasonable.Given the promising preclinical results and reasonable IPO price valuation assumption, for life science investors with a long-term hold time frame, on the IPO is a BUY at up to $5.50 per share.